Hengrui Pharma debuts at #ESMO2025, presents 46 oncology studies

From translating academic research to designing clinical trials, founders across Texas are turning scientific breakthroughs into real-world impact with the help of TMC Innovation’s Accelerator for Cancer Therapeutics (ACT). In this blog, we spotlight three companies—OmniNano Pharmaceuticals, LLC, Barricade Therapeutics, and Mongoose Bio Inc.—whose founders, Dr. Chun Li, Neil Thapar, and Dr. Cassian Yee, transformed promising ideas into scalable cancer therapies with support from ACT. Their success underscores why Houston continues to rise as a global hub for oncology innovation, where collaboration fuels discovery and every breakthrough brings us closer to better patient outcomes. Discover their stories and learn more about ACT’s impact on Texas's life science landscape: 🔗: https://lnkd.in/gHa_C5gT #OncologyInnovation #CancerTherapeutics #HoustonBiotech #TMCInnovation #HealthcareInnovation #LifeScienceEcosystem

It’s always inspiring to tell the stories of founders who are turning their breakthroughs into real-world impact. The Accelerator for Cancer Therapeutics (ACT) program continues to prove that collaboration and mentorship can accelerate oncology innovation across Texas. I’m grateful to Neil Thapar, Chun Li, and Cassian Yee, who shared their journey.  Read how ACT is helping launch the future of oncology innovation: 🔗 https://lnkd.in/gHZg5jVe #Oncology #LifeSciences #CancerTherapeutics #TMCInnovation #Storytelling #TexasMedicalCenter

The 50th anniversary of the European Society for Medical Oncology (ESMO) Congress #ESMO25 showcased how fast oncology is transforming toward data-driven, biomarker-guided care. Our comprehensive analysis, now live https://lnkd.in/dypR3Ctk,  summarizes data from selected 60+ abstracts across leading diagnostic developers and testing providers, alongside key clinical breakthroughs shaping therapy selection. By the numbers: Natera – 16 abstracts: Multi-tumor ctDNA MRD evidence confirming Signatera™ as a predictive biomarker guiding adjuvant immunotherapy and treatment de-escalation. Guardant Health – 15 abstracts: Validation of Guardant Reveal™ as a plasma-only MRD test across CRC, lung, and head-and-neck cancers — with decision-impact data showing how ctDNA results change oncologist behavior. Foundation Medicine – 12 abstracts: Multi-omic CGP (DNA + RNA) defining HRD signatures, ESR1/AR-V7 fusions, and resistance pathways across ovarian, breast, and rare tumors. Tempus AI – 6 abstracts: Integration of AI, RNA-based subtyping, and real-world data to personalize therapy in renal, prostate, and lung cancer. Bio-Rad Laboratories-Rad – 6 abstracts: Digital PCR (ddPCR) emerging as a scalable hospital-based platform for MRD quantification and resistance monitoring. Beyond the data, ESMO 2025 reflected several defining trends: - MRD maturity: More than 25 studies showed ctDNA or methylation-based MRD assays moving from validation to clinical decision-making — including adjuvant therapy guidance and recurrence monitoring. - Convergence of diagnostics and therapeutics: Multi-omic CGP and ctDNA results increasingly featured in prospective interventional trials, blurring lines between biomarker discovery and clinical practice. - Policy momentum: New cost-effectiveness and implementation models (France, Ireland, Norway) show how genomic testing is becoming embedded in health-system strategy, not just research. - Therapy innovation: #ADCs, bispecific IO combinations, and radioligand therapies continued to expand treatment frontiers, supported by biomarker-driven trial designs. Explore the full Precision Oncology Consulting ESMO 2025 Takeaways including company-level summaries, policy analyses, and therapeutic highlights at https://lnkd.in/d_dFDgmF (In our analysis we’ve included only the companies for which we’ve had easy access to presented data. If you’d like your company to be featured in future editions, do reach out! Filtering on the ESMO congress website remains, let’s say… a bit of a challenge.) #ESMO2025 #PrecisionOncology #Diagnostics #LiquidBiopsy #MRD #CGP #AIinOncology #OncologyInnovation #MarketAccess #CancerResearch

Clinical trials move at the speed of paperwork, but they don't have to. Tomorrow, our CMO and Head of Strategy, Chadi Nabhan, MD, MBA,FACP presents at Biocom California's Innovations in Oncology Clinical Trial Design conference, hosted by UC San Diego Moores Cancer Center His session on AI Applications for Clinical Trial Efficiency will explore how AI is solving the industry's biggest challenges, from trial design to patient recruitment, to regulatory approval. Learn more about the event here: https://lnkd.in/gB97TE47 #ClinicalResearch #AI #Pharma #Biotech #DrugDiscovery #AIClinicalTrials

🚀 Exciting Advancement in Prostate Cancer Treatment! 🚀 GlaxoSmithKline has acquired worldwide development and commercial rights to a pioneering antibody-drug conjugate developed by Syndivia, marking a bold step forward in tackling metastatic castration-resistant prostate cancer. This innovative therapy, leveraging Syndivia’s proprietary GeminiMab conjugation technology, has demonstrated strong anti-tumor activity with a promising safety profile in preclinical studies. With global prostate cancer diagnoses nearing 1.4 million annually and limited effective treatment options for advanced stages, this acquisition aims to address critical gaps in care—especially in community practice settings. The agreement reflects GlaxoSmithKline’s strategic commitment to expanding its oncology portfolio beyond traditional areas, incorporating novel modalities such as antibody-drug conjugates, T-cell engagers, and small molecules. Financially, the collaboration includes an initial payment and potential milestones totaling up to £268 million, alongside royalties to Syndivia on future sales. This partnership underscores a patient-focused approach, offering hope for significant improvements in prostate cancer management worldwide. #AntibodyDrugConjugate #CancerResearch #GlaxoSmithKline #HealthcareInnovation #Oncology #Partnership #PatientCare #Pharma #PharmaceuticalCompanies #ProstateCancer #Syndivia #MarketAccess #MarketAccessToday

Headline: Unlocking the Future of Oncology: Datopotamab - Deruxtecan, a New Standard A major congratulations to Daiichi Sankyo & AstraZeneca on the recent launch of Datopotamab, Deruxtecan (Datroway), a next-generation antibody-drug conjugate for patients living with metastatic non-small cell lung cancer and advanced breast cancer. This approval is a milestone in targeted therapy and multi-regional launch excellence. Here’s why senior industry leaders are watching this launch closely: Peak sales forecast: $3+ billion globally, reinforcing the enormous commercial and patient impact of advanced ADCs. Clinical breakthrough: Datroway demonstrated a significant improvement in progression-free survival (PFS) over standard chemotherapy in high-risk, previously treated adult patients. Rapid access: Approved in the US, Europe, and Japan within 12 months of pivotal trial readout, showcasing regulatory agility and cross-border launch orchestration. At ConformanceX, we believe AI-powered platforms like BrandLaunchX are pivotal for streamlining complex, multi-regional drug launches, enabling faster access for patients who need breakthrough therapies the most. How do you see digital and data-driven approaches changing the landscape for novel oncology product launches worldwide? #DrugLaunch #Oncology #ADC #Innovation #ConformanceX #BrandLaunchX

Korean biotechs -- GC Cell, NeoImmuneTech, NOBO Medicine, and Orum Therapeutics -- will unveil new CAR-T, CAR-NK, and ADC data at the upcoming annual meeting of the American Society of Hematology, showcasing the nation’s expanding capabilities in blood cancer research. #ASH2026 #bloodcancer #hematology #ADC #CART https://lnkd.in/eZh525nj

Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital™ PCR High Complexity Assays. Read the press release for more information: https://lnkd.in/ghkF5bEt #Biodesix #BioRad #PrecisionMedicine #oncology #PersonalizedDiagnostics

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting https://lnkd.in/eVa_-GYc #HCWB #TCellEngager #AntiCancer #Immunotherapy

GSK acquires Syndivia’s preclinical ADC for prostate cancer in US$357M deal. #GSK #Syndivia #ProstateCancer #ADC #PharmaNews #Oncology #Biotech https://lnkd.in/dKuv7fCv